Nongastric marginal zone B-cell lymphoma: Analysis of 247 cases

American Journal of Hematology

Volumn 82, Issue 6, 2007, Pages 446-452

  Sung, Yong Oh ^a   Ryoo, Baek Yeol ^b   Won, Seog Kim ^a   Yeon, Hee Park ^b   Kim, Kihyun ^a   Hyun, Jung Kim ^a   Jung, Mi Kwon ^a   Lee, Jeeyun ^a   Young, Hye Ko ^c   Yong, Chan Ahn ^c   Suk, Joong Oh ^d   Soon, Il Lee ^e   Kim, Hyo Jin ^f   Kwon, Hyuk Chan ^f   Soo, Mee Bang ^g   Jung, Han Kim ^h   Park, Jinny ⁱ   Lee, Seung Sook ^b   Ho, Young Kim ^j   Park, Keunchil ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

^b Korea Institute of Radiation and Medical Science   (South Korea)

^c Sungkyunkwan University   (South Korea)

^d Sungkyunkwan University School of Medicine   (South Korea)

^e Dankook University   (South Korea)

^f Dong A University   (South Korea)

^g Gachon University College of Medicine   (South Korea)

^h Hallym University   (South Korea)

ⁱ Cheju Universisity College of Medicine   (South Korea)

^j Yonsei University Wonju College of Medicine   (South Korea)

more..

Author keywords

Critical presentations; Marginal zone B cell lymphoma; Nongastric; Treatment

Indexed keywords

ANTHRACYCLINE; BLEOMYCIN; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; FLUDARABINE; PREDNISOLONE; PREDNISONE; PROCARBAZINE; VINCRISTINE;

ADULT; AGED; ARTICLE; B CELL LYMPHOMA; CANCER PATIENT; CANCER REGRESSION; CANCER STAGING; CANCER SURVIVAL; CLINICAL FEATURE; FEMALE; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; TREATMENT INDICATION; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; COHORT STUDIES; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; LYMPHOMA, B-CELL, MARGINAL ZONE; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; RECURRENCE; REMISSION INDUCTION; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 34249784236     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.20874     Document Type: Article

References (29)

1. Thieblemont C, Berger F, Dumontet C, et al. Mucosa-associated lymphoid tissue lymphoma is a disseminated disease in one third of 158 patients analyzed. Blood 2000;95:802-806.
2. Zucca E, Conconi A, Pedrinis E, et al. Nongastric marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue. Blood 2003;101:2489-2495.
3. Zinzani PL, Magagnoli M, Galieni P, et al. Nongastrointestinal low-grade mucosa-associated lymphoid tissue lymphoma: Analysis of 75 patients. J Clin Oncol 1999;17:1254-1258.
4. Isaacson PG. Update on MALT lymphomas. Best Pract Res Clin Haematol 2005;18:57-68.
5. Wenzel C, Fiebiger W, Dieckmann K, Formanek M, Chott A, Raderer M. Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue of the head and neck area: High rate of disease recurrence following local therapy. Cancer 2003;97:2236-2241.
6. Lee JL, Kim MK, Lee KH, et al. Extranodal marginal zone B-cell lymphomas of mucosa-associated lymphoid tissue-type of the orbit and ocular adnexa. Ann Hematol 2005;84:13-18.
7. Ko YH, Kim CW, Park CS, et al. REAL Classification of malignant lymphomas in the Republic of Korea. Cancer 1998;83:806-812.
8. Ahmed S, Kussick SJ, Siddiqui AK, et al. Bronchial-associated lymphoid tissue lymphoma: A clinical study of a rare disease. Eur J Cancer 2004;40:1320-1326.
9. Kim JH, Lee SH, Park J, et al. Primary pulmonary non-Hodgkin's lymphoma. Jpn J Clin Oncol 2004;34:510-514.
10. Nathwani BN, Anderson JR, Armitage JO, et al. Marginal zone B-cell lymphoma: A clinical comparison of nodal and mucosa-associated lymphoid tissue types. J Clin Oncol 1999;17:2486-2492.
11. Conconi A, Bertoni F, Pedrinis E, et al. Nodal marginal zone B-cell lymphomas may arise from different subsets of marginal zone B lymphocytes. Blood 2001;98:781-786.
12. Berger F, Felman P, Thieblemont C, et al. Non-MALT marginal zone B-cell lymphomas: A description of clinical presentation and outcome in 124 patients. Blood 2000;95:1950-1956.
13. Vallisa D, Bernuzzi P, Arcaini L, et al. Role of anti-hepatitis C virus (HCV) treatment in HCV-related, low-grade, B-cell, non-Hodgkin's lymphoma: A multicenter Italian experience. J Clin Oncol 2005;23:468-473.
14. Ferreri AJ, Guidoboni M, Ponzoni M, et al. Evidence for an association between Chlamydia psittaci and ocular adnexal lymphomas. J Natl Cancer Inst 2004;96:586-594.
15. Tsang RW, Gospodarowicz MK, Pintilie M, et al. Localized mucosa-associated lymphoid tissue lymphoma treated with radiation therapy has excellent clinical outcome. J Clin Oncol 2003;21:4157-4164.
16. Fung CY, Tarbell NJ, Lucarelli MJ, et al. Ocular adnexal lymphoma: Clinical behavior of distinct World Health Organization classification subtypes. Int J Radiat Oncol Biol Phys 2003;57:1382-1391.
17. Park W, Chang SK, Yang WI, et al. Rationale for radiotherapy as a treatment modality in gastric mucosa-associated lymphoid tissue lymphoma. Int J Radiat Oncol Biol Phys 2004;58:1480-1486.
18. Raderer M, Streubel B, Woehrer S, et al. High relapse rate in patients with MALT lymphoma warrants lifelong follow-up. Clin Cancer Res 2005;11:3349-3352.
19. Jager G, Neumeister P, Brezinschek R, et al. Treatment of extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue type with cladribine: A phase II study. J Clin Oncol 2002;20:3872-3877.
20. Zinzani PL, Stefoni V, Musuraca G, et al. Fludarabine-containing chemotherapy as frontline treatment of nongastrointestinal mucosa-associated lymphoid tissue lymphoma. Cancer 2004;100:2190-2194.
21. Hammel P, Haioun C, Chaumette MT, et al. Efficacy of single-agent chemotherapy in low-grade B-cell mucosa-associated lymphoid tissue lymphoma with prominent gastric expression. J Clin Oncol 1995;13:2524-2529.
22. Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas.NCI Sponsored International Working Group. J Clin Oncol 1999;17:1244-1253.
23. Oh SY, Kim WS, Kim JH, et al. Extra-gastric MALT lymphoma: Analysis of 50 cases. Korean J Med 2000;59:261-267.
24. Park KS, Lee YS, Lee SG, et al. A study on markers of viral hepatitis in adults living in Daegu and Gyungbuk Area. Korean J Gastroenterol 2003;41:473-479.
25. Ardeshna KM, Smith P, Norton A, et al. Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: A randomised controlled trial. Lancet 2003;362:516-522.
26. Bennett M, Sharma K, Yegena S, Gavish I, Dave HP, Schechter GP. Rituximab monotherapy for splenic marginal zone lymphoma. Haematologica 2005;90:856-858.
27. Martinelli G, Laszlo D, Ferreri AJ, et al. Clinical activity of rituximab in gastric marginal zone non-Hodgkin's lymphoma resistant to or not eligible for anti-Helicobacter pylori therapy. J Clin Oncol. 2005;23:1979-1983.
28. O'Connor OA, Wright J, Moskowitz C, et al. Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma. J Clin Oncol 2005;23:676-684.
29. Brown JR, Gaudet G, Friedberg JW, et al. Autologous bone marrow transplantation for marginal zone non-Hodgkin's lymphoma. Leuk Lymphoma 2004;45:315-320.